Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S‑1 chemotherapy

  • Authors:
    • Kei Hosoda
    • Keishi Yamashita
    • Hideki Ushiku
    • Akira Ema
    • Hiromitsu Moriya
    • Hiroaki Mieno
    • Marie Washio
    • Masahiko Watanabe
  • View Affiliations

  • Published online on: December 5, 2017     https://doi.org/10.3892/ol.2017.7515
  • Pages:1853-1860
Metrics: HTML 0 views | PDF 0 views     Cited By: 0 citations

Abstract

Curative gastrectomy and adjuvant chemotherapy using S‑1 is a standard treatment for stage II/III gastric cancer in Japan. The purpose of the present study was to evaluate the prognostic relevance of fibroblast growth factor receptor (FGFR)2 expression in patients with stage II/III gastric cancer that underwent postoperative adjuvant chemotherapy with S‑1. Formalin‑fixed paraffin‑embedded surgical specimens were retrospectively examined in 167 patients with stage II/III gastric cancer that underwent curative gastrectomy followed by adjuvant S1 chemotherapy. FGFR2 expression was measured using immunohistochemistry (IHC) staining. The IHC results for FGFR2 were as follows: Grade 1+, 32; grade 2+, 80; grade 3+, 55 patients. The FGFR2 expression level was not significantly associated with relapse‑free or overall survival rates. However, in the diffuse type, the FGFR2 expression level tended to be negatively correlated with relapse‑free survival. In particular, the proportion of patients who recurred >5 years following surgery was significantly larger in the FGFR2 grade 3+ group than in the grade 1+, 2+ group (4/22 vs. 1/35; P=0.047). The recurrent sites of long‑term failure were mostly peritoneum among the diffuse type. To the best of our knowledge, the present study indicated for the first time that FGFR2 could predict long‑term failure of adjuvant S‑1 chemotherapy in curative advanced gastric cancer. There was no interaction between FGFR2 expression and patient survival outcomes in stage II/III gastric cancer. Patients with FGFR2 3+ in stage II/III gastric cancer should carefully be followed‑up for >5 years after surgery.

Related Articles

Journal Cover

February 2018
Volume 15 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Hosoda, K., Yamashita, K., Ushiku, H., Ema, A., Moriya, H., Mieno, H. ... Watanabe, M. (2018). Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S‑1 chemotherapy. Oncology Letters, 15, 1853-1860. https://doi.org/10.3892/ol.2017.7515
MLA
Hosoda, K., Yamashita, K., Ushiku, H., Ema, A., Moriya, H., Mieno, H., Washio, M., Watanabe, M."Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S‑1 chemotherapy". Oncology Letters 15.2 (2018): 1853-1860.
Chicago
Hosoda, K., Yamashita, K., Ushiku, H., Ema, A., Moriya, H., Mieno, H., Washio, M., Watanabe, M."Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S‑1 chemotherapy". Oncology Letters 15, no. 2 (2018): 1853-1860. https://doi.org/10.3892/ol.2017.7515